Sep 14, 2022 / 04:55PM GMT
Michael Eric Ulz - Morgan Stanley, Research Division - Equity Analyst
All right. Good afternoon, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference. I'm Michael Ulz, one of the biotech analysts here. And it's my pleasure to introduce the team from Fusion Pharmaceuticals, starting with John Crowley, CFO; as well as Eric Burak, Chief Technology Officer.
But before we get started today, I just need to read a quick disclaimer. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please feel free to reach out to your Morgan Stanley sales rep. With that we can jump right in the Q&A.
Questions and Answers:
Michael Eric Ulz - Morgan Stanley, Research Division - Equity AnalystJohn and Eric, thanks for joining us today. And maybe for people who aren't familiar with Fusion and more broadly, radiopharmaceuticals, if you can